Evaluation of the mechanism of Action of talimogene laherparepvec (T-VEC) in patients with locally advanced non-melanoma skin cancer.
This study evaluates the administration of T-VEC in non-melanoma skin cancer. The aim is to evaluate the effectiveness, safety and tolerability of T-VEC in patients with non-melanoma skin cancer through determination of local immune effects after repeated T-VEC injections.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
26
a modified herpes simplex virus-1 (HSV-1) containing the gene coding for human granulocyte macrophage colony-stimulating factor (GM-CSF)
Department of Dermatology, University Hospital Zurich
Zurich, Switzerland
Change from Baseline local immune effects after repeated T-VEC injections
Detection of increased local immune activation markers in skin biopsies of injected lesions. The following markers will be assessed by Polymerase chain reaction (PCR): interferon (IFN), 2-prime, 5-prime oligoadenylate synthetase 1 (OAS1), Interferon-induced GTP-binding protein MxA (MXA) and C-X-C motif chemokine 11 (CXCL11)
Time frame: at baseline, after 3 injections (week 6) and optionally after 6 injections (week 12)
Detection of Tumor Regression using World Health Organization (WHO) response criteria
Measurement of the treated tumor size will be performed at baseline and at each visit until end of the study
Time frame: at baseline and at week 22
Systemic immune response
Detection of increased systemic immune Response markers in sera and peripheral blood mononuclear cells by multi-Color fluorescence-activated cell sorting (FACS)
Time frame: at baseline and week 6, optionally also at week 12
Analysis of Adverse events
All serious and non-serious adverse events that occur after enrollment through 30 (+7) days after the last administration of T-VEC will be recorded
Time frame: At week 1, 4, 6, 8, 10, 12, 14, 16, 18, 22
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.